Literature DB >> 17043157

Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.

James M Luther1, James V Gainer, Laine J Murphey, Chang Yu, Douglas E Vaughan, Jason D Morrow, Nancy J Brown.   

Abstract

This study tested the hypothesis that angiotensin promotes oxidative stress and inflammation in humans via aldosterone and the mineralocorticoid receptor. We measured the effect of intravenous aldosterone (0.7 mug/kg per hour for 10 hours followed by 0.9 mug/kg per hour for 4 hours) and vehicle in a randomized, double-blind crossover study in 11 sodium-restricted normotensive subjects. Aldosterone increased interleukin (IL)-6 (from 4.7+/-4.9 to 9.4+/-7.1 pg/mL; F=4.94; P=0.04) but did not affect blood pressure, serum potassium, or high-sensitivity C-reactive protein. We next conducted a randomized, double-blind, placebo-controlled, crossover study to measure the effect of 3-hour infusion of angiotensin II (2 ng/kg per minute) and norepinephrine (30 ng/kg per minute) on separate days after 2 weeks of placebo or spironolactone (50 mg per day) in 14 salt-replete normotensive subjects. Angiotensin II increased blood pressure (increase in systolic pressure: 13.7+/-7.5 and 15.2+/-9.4 mm Hg during placebo and spironolactone, respectively; P<0.001 for angiotensin II) and decreased renal plasma flow (-202+/-73 and -167+/-112 mL/min/1.73 kg/m(2); P<0.001 for angiotensin II effect) similarly during placebo and spironolactone. Spironolactone enhanced the aldosterone response to angiotensin II (increase of 17.0+/-10.6 versus 9.0+/-5.7 ng/dL; P=0.002). Angiotensin II transiently increased free plasma F(2)-isoprostanes similarly during placebo and spironolactone. Angiotensin II increased serum IL-6 concentrations during placebo (from 1.8+/-1.1 to 2.4+/-1.4 pg/mL; F=4.5; P=0.04) but spironolactone prevented this effect (F=6.4; P=0.03 for spironolactone effect). Norepinephrine increased blood pressure and F(2)-isoprostanes but not aldosterone or IL-6. Aldosterone increases IL-6 in humans. These data suggest that angiotensin II induces IL-6 through a mineralocorticoid receptor-dependent mechanism in humans. In contrast, angiotensin II-induced oxidative stress, as measured by F(2)-isoprostanes, is mineralocorticoid receptor independent and may be pressor dependent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043157     DOI: 10.1161/01.HYP.0000248135.97380.76

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  57 in total

1.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

Review 2.  Inflammation and therapy for hypertension.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

3.  Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells.

Authors:  Ke Li; Dehuang Guo; Haidong Zhu; Kathleen S Hering-Smith; L Lee Hamm; Jingping Ouyang; Yanbin Dong
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-26       Impact factor: 3.619

Review 4.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 5.  Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease.

Authors:  Laura D Kubzansky; Gail K Adler
Journal:  Neurosci Biobehav Rev       Date:  2009-07-22       Impact factor: 8.989

Review 6.  Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction.

Authors:  William J Welch
Journal:  Hypertension       Date:  2008-05-12       Impact factor: 10.190

7.  Interleukin-6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats.

Authors:  Shireen Hashmat; Nathan Rudemiller; Hayley Lund; Justine M Abais-Battad; Scott Van Why; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-08

8.  Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans.

Authors:  James M Luther; Loretta M Byrne; Chang Yu; Thomas J Wang; Nancy J Brown
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

Review 9.  The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension.

Authors:  David G Harrison
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

Review 10.  Inflammation, immunity, and hypertensive end-organ damage.

Authors:  William G McMaster; Annet Kirabo; Meena S Madhur; David G Harrison
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.